Ensign Peak Advisors
MRSN

Ensign Peak Advisors’s Mersana Therapeutics MRSN Stock Holding History

Ensign Peak Advisors’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-893
Closed -$151K – 2060
2022
Q3 		$151K Buy
893
+531
+147% +$86.3K ﹤0.01% 1974
2022
Q2 		$42K Hold
362
– – ﹤0.01% 2082
2022
Q1 		$36K Hold
362
– – ﹤0.01% 2154
2021
Q4 		$56K Buy
+362
New +$70.4K ﹤0.01% 2131

Other funds holding MRSN

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Ensign Peak Advisors's MRSN Position: Q4 2022 in Review

Ensign Peak Advisors sold out of Mersana Therapeutics (MRSN) in Q4 2022, closing a stake of 893 shares — an estimated $151K sold.

Ensign Peak Advisors first reported a position in MRSN in Q4 2021 and held it in 4 quarters. The position peaked at $151K in Q3 2022. 152 funds tracked by Wall St. Rank hold MRSN as of Q4 2022.

  • Ensign Peak Advisors reported no remaining Mersana Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 893 Mersana Therapeutics shares in Q4 2022, an estimated $151K.
  • Ensign Peak Advisors first reported a position in Mersana Therapeutics in Q4 2021 and held it in 4 quarters.
  • Ensign Peak Advisors's Mersana Therapeutics position peaked at $151K in Q3 2022.
  • 152 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.